Ernexa Therapeutics logo
Ernexa Therapeutics
ERNA | NASDAQ
Chart Builder DCF Calculator
$1.69
+$0.01 (+0.60%)
At close: Nov 16, 2026, 4:00 PM ET
$1.68
-$0.01 (-0.59%)
After-hours: Nov 16, 2026, 5:58 PM ET

Ernexa Therapeutics Company Profile

Company profile explained

Company Profile

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

Key Executives

Name Position
Sanjeev Luther Chief Executive Officer, President & Director
Mark J. Keeley CITP Chief Financial Officer
Deborah Vee Wild Head of CMC & Operations
Dorothy J. Clarke General Counsel
Kanika Chawla Senior Vice President of Technical Operations (Consultant)
Robert Hamilton Pierce Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 15, 2026 8-K Current Report
Sep 22, 2026 3 Filing
Sep 16, 2026 8-K Current Report
Sep 16, 2026 8-K Current Report
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
View All SEC Filings ➞
Ernexa Therapeutics
Ernexa Therapeutics logo
Country United States
IPO Date Aug 29, 1991
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Sanjeev Luther

Contact Details

10355 Science Center Drive Cambridge, Massachusetts 02141 United States

Stock Details

Ticker Symbol ERNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000748592
CUSIP Number 114082407
ISIN Number US1140824079
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.